| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PFDN6 |
| Uniprot No | O15212 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-129aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAELIQKKLQGEVEKYQQLQKDLSKSMSGR QKLEAQLTENNIVKEELALLDGSNVVFKLLGPVLVKQELGEARATVGKRL DYITAEIKRYESQLRDLERQSEQQRETLAQLQQEFQRAQAAKAGAPGKA |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PFDN6重组蛋白的3篇模拟参考文献及其摘要概述(注：以下文献为示例，非真实存在)：
---
1. **文献名称**：*Structural Insights into the Prefoldin Subunit PFDN6 and Its Role in Protein Folding*
**作者**：Zhang, Y. et al.
**期刊/年份**：*Biochemical Journal*, 2015
**摘要概述**：该研究通过重组表达人源PFDN6蛋白，利用X射线晶体学解析其三维结构，揭示了其与伴侣蛋白复合体其他亚基的相互作用界面，并证明其在体外可促进特定底物蛋白的正确折叠。
---
2. **文献名称**：*Recombinant PFDN6 Enhances Oncogenic Signaling via Stabilization of MAPK Pathway Components*
**作者**：Wang, L. et al.
**期刊/年份**：*Cell Reports*, 2018
**摘要概述**：研究团队通过重组PFDN6蛋白的过表达实验，发现其通过结合并稳定MAPK信号通路中的关键激酶(如ERK1/2)，促进肿瘤细胞增殖，为靶向癌症治疗提供了潜在新靶点。
---
3. **文献名称**：*PFDN6 Recombinant Protein Suppresses α-Synuclein Aggregation in Parkinson's Disease Models*
**作者**：Chen, X. et al.
**期刊/年份**：*Journal of Biological Chemistry*, 2020
**摘要概述**：该研究利用重组PFDN6蛋白处理α-synuclein过表达的神经元模型，发现其显著减少异常蛋白聚集，并缓解线粒体功能障碍，提示PFDN6在神经退行性疾病中的保护作用。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“PFDN6 recombinant protein”或“PFDN6 prefoldin function”。
**Background of PFDN6 Recombinant Protein**
PFDN6 (Prefoldin Subunit 6), also known as URI1 or MAPKSP1. is a member of the prefoldin chaperone protein family, which plays a critical role in assisting proper folding of nascent polypeptides and maintaining proteostasis. The prefoldin complex, composed of six subunits (PFDN1-6), acts as a co-chaperone by binding to unfolded proteins and delivering them to group II chaperonins like the CCT (chaperonin-containing TCP-1) complex for further folding. PFDN6. encoded by the *PFDN6* gene in humans, is unique among prefoldin subunits due to its additional roles in transcriptional regulation and cellular signaling pathways, particularly those involving the MAPK/ERK cascade.
Recombinant PFDN6 protein is engineered for experimental studies to explore its structural and functional properties. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cell lines), the recombinant protein retains the ability to interact with partner molecules, enabling researchers to investigate its chaperone activity, involvement in protein quality control, and links to diseases. Dysregulation of PFDN6 has been implicated in cancer progression, neurodegenerative disorders, and developmental defects, making it a potential therapeutic target.
The recombinant form is often tagged (e.g., His-tag) for purification and detection, facilitating applications such as protein-protein interaction assays, enzymatic studies, and antibody development. Its study contributes to understanding cellular stress responses, cancer biology, and mechanisms underlying protein misfolding diseases.
×
